Therapeutic potential of antiidiotypic single chain antibodies with yeast killer toxin activity.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 9035141.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Single chain fragment (ScFv) antiidiotypic antibodies (antilds) of a killer toxin (KT) from the yeast Pichia anomala have been produced by recombinant DNA methodology from the splenic lymphocytes of mice immunized by idiotypic vaccination with a KT-neutralizing monoclonal antibody (Mab KT4). ScFv KT-like antilds (KTIdAb) react with specific Candida albicans KT cell wall receptors (KTR) exerting a candidacidal activity in vitro could be neutralized by adsorption with Mab KT4. ScFv KTIdAb displayed an effective therapeutic activity in an experimental model of rat candidal vaginitis.
Medical subject headings
- Antibodies, Anti-Idiotypic
- Antibodies, Monoclonal
- Candidiasis, Vulvovaginal
- Immunotoxins
- Mycotoxins